utilized data from this trial to file for CE Mark approval of the GALILEO System.
We value the strength of our intellectual property portfolio and we will continue to pursue legal actions against products that we believe infringe our patents, such as the Guidant
Vision and Xience stents and the Boston Scientific Taxus stent," said Scott Ward, Medtronic senior vice president and president of Medtronic Vascular, Santa Rosa, Calif.
Corporation (NYSE:GDT) today announced that the company has completed enrollment of 1,002 patients in the randomized U.
Corporation is a world leader in the treatment of cardiac and vascular disease.
On December 15, 2004, defendants announced that Guidant
had been sold to Johnson & Johnson ("J&J") for approximately $25 billion in cash and J&J stock, within an imputed value of approximately $76 per share.
Corporation (NYSE:GDT) today announced Conformite Europeenne (CE) Mark approval of its ACUITY(R) Steerable heart failure lead.
Cornelius commented, "The Board is especially thankful to Ron and the senior management group for their efforts, as well as the 12,000 Guidant
employee-owners around the globe, during the last eleven months of balancing transition planning and addressing our business challenges.
INDIANAPOLIS -- Guidant
Corporation (NYSE:GDT) announced today that it has received a warning letter from the U.
's Rating Watch Positive status reflects the positive credit implications for Guidant
from being acquired by the 'AAA' rated JNJ.
The FDA provided Guidant
Cardiac Rhythm Management with a Form 483, noting observations related to quality system requirements.
While neither company depends on this transaction for its continued future success, Guidant
believes that the strategic rationale for combining the two companies is as strong today as when we entered into the Merger Agreement.
The change in the Rating Watch reflects the uncertainty surrounding whether 'AAA' rated Johnson & Johnson's (JNJ) pending $24 billion acquisition of Guidant
will be consummated given the recent comments from JNJ.
In addition to the CAPTURE and ARCHeR series of trials, Guidant
is participating in the CREST trial evaluating carotid artery stenting in low-surgical risk patients, which continues to enroll.
INDIANAPOLIS -- We at Guidant
Corporation (NYSE:GDT) take seriously the issues raised in the October 20 article in The New York Times titled: Behind Heart Implants, a History of Defects and a Repeated Error.
product approvals, such as the LATITUDE(R) Patient Management system, reflect Guidant
's commitment to providing physicians and patients a broad array of therapeutic options for the prevention of sudden cardiac death and the treatment of heart failure," said Fred McCoy, president, Cardiac Rhythm Management, Guidant